Literature DB >> 8721278

A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography.

N Ratnaraj1, H C Doheny, P N Patsalos.   

Abstract

An isocratic high performance liquid chromatographic micromethod is described for the quantitation of levetiracetam (ucb L059) in plasma or serum of patients. The chromatography is performed on a 250 x 4 mm I.D. LiChrospher 60 RP-select B, 5-micron column, eluted with an acetonitrile/50 mM phosphate buffer (15:85 vol/vol, pH 5.6) mobile phase, and levetiracetam detected using ultraviolet absorbance at 220 nm. The limit of quantitation was 5 mumol/L and the within-batch and between-batch coefficients of variation were < 7%. No interference from commonly prescribed antiepileptic drugs (carbamazepine and its metabolite carbamazepine epoxide, ethosuximide, gabapentin, lamotrigine, phenobarbitone, phenytoin, primidone, valproic acid, and vigabatrin) was observed, and thus the method can be used to monitor levetiracetam in patients on polytherapy antiepileptic drug regimens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721278     DOI: 10.1097/00007691-199604000-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  14 in total

1.  Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin.

Authors:  Bjørnar Hassel; Erik Taubøll; Renee Shaw; Leif Gjerstad; Ray Dingledine
Journal:  Epilepsia       Date:  2010-09       Impact factor: 5.864

2.  A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy.

Authors:  H C Doheny; M A Whittington; J G R Jefferys; P N Patsalos
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Cytisine inhibits the protective activity of various classical and novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice.

Authors:  Piotr Tutka; Maria W Kondrat-Wróbel; Katarzyna Zaluska; Dorota Żółkowska; Magdalena Florek-Łuszczki; Jarogniew J Łuszczki
Journal:  Psychopharmacology (Berl)       Date:  2016-10-25       Impact factor: 4.530

4.  A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain.

Authors:  X Tong; P N Patsalos
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 5.  Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy.

Authors:  Jason Tan; Vanessa Paquette; Marc Levine; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

6.  Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.

Authors:  Matthew D Krasowski
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-11

7.  Levetiracetam.

Authors:  M Haria; J A Balfour
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

8.  Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes.

Authors:  Elena A Matveeva; Thomas C Vanaman; Sidney W Whiteheart; John T Slevin
Journal:  Epilepsia       Date:  2008-05-29       Impact factor: 5.864

Review 9.  Clinical pharmacokinetics of levetiracetam.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography tandem mass spectrometry.

Authors:  Li-Ling Yeap; Yoke-Lin Lo
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.